Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
about
Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?Smad1-Smad5 ovarian conditional knockout mice develop a disease profile similar to the juvenile form of human granulosa cell tumors.Constitutively active transforming growth factor β receptor 1 in the mouse ovary promotes tumorigenesisGranulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development.Loss of inhibin alpha uncouples oocyte-granulosa cell dynamics and disrupts postnatal folliculogenesis.Absence of inhibin alpha and retinoblastoma protein leads to early sertoli cell dysfunctionLoss of betaglycan contributes to the malignant properties of human granulosa tumor cells.The ovary: basic biology and clinical implicationsGenetic evidence that SMAD2 is not required for gonadal tumor development in inhibin-deficient miceDefective gonadotropin-dependent ovarian folliculogenesis and granulosa cell gene expression in inhibin-deficient mice.Inhibin at 90: from discovery to clinical application, a historical reviewTGFβ signaling promotes juvenile granulosa cell tumorigenesis by suppressing apoptosis.Treating cancer cachexia to treat cancerDevelopment of novel activin-targeted therapeutics.New insights into ovarian function.Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatinVirtual High-Throughput Screening To Identify Novel Activin Antagonists.The skeletal muscle secretome: an emerging player in muscle-bone crosstalkActivin signaling as an emerging target for therapeutic interventionsThe mammalian ovary from genesis to revelation.Role of activin in bacterial infections: a potential target for immunointervention?Activin receptor antagonists for cancer-related anemia and bone disease.Activin, neutrophils, and inflammation: just coincidence?The TGF-β Family in the Reproductive Tract.SMAD3 Activation: A Converging Point of Dysregulated TGF-Beta Superfamily Signaling and Genetic Aberrations in Granulosa Cell Tumor Development?Activin-β(c) reduces reproductive tumour progression and abolishes cancer-associated cachexia in inhibin-deficient mice.Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis.Receptors and signaling pathways involved in proliferation and differentiation of Sertoli cells.Follistatin is critical for mouse uterine receptivity and decidualization.Disruption of postnatal folliculogenesis and development of ovarian tumor in a mouse model with aberrant transforming growth factor beta signaling.Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
P2860
Q28068034-9555F8F6-B0E7-40EF-9B2C-6620F79C2004Q30040477-03543150-A210-4487-91A1-44611E4ACA62Q30354729-D6430C91-56E0-4F09-91E5-8E9B65F157E6Q30432180-6F899E2C-E496-4065-A7B6-6500BD09187FQ30434519-73C82B63-D371-4495-B39C-EB14A2B7DD1BQ30435377-659D2FCE-77C7-41BB-BCEA-AF7CD7C3DEB2Q33642461-99099FB5-4361-441D-9297-FCB0042EE2B6Q33755421-4118FF48-118F-4EC2-8F10-13A207BC5E34Q33992203-854F03A2-2D35-4AE8-AA18-1DA95A54085CQ34157558-F94F9C5E-5E53-4C87-9E1D-CB0FFEB7D1BCQ34204531-22BEE3C0-8163-40F8-9314-B5AACA6C2E73Q34422499-38EB35C8-F014-42DF-A684-2D98379FD941Q35128695-843A8A60-70FE-4F97-9B5B-9377FDD75238Q35153096-5F68D15C-C194-428E-B529-1D1F98FA350BQ36001078-F5BDBC6A-9FE6-4233-8D49-A0393A297AA6Q36062074-24D0E925-B35C-4B08-AE8B-D0F67F21E1A0Q36256670-1D118584-F500-473D-86B3-13C84C470D07Q37056395-50AB43C1-E2B5-43F8-BD9B-5C52A364F10DQ37268461-C3E083E4-4899-41A5-9522-0FB4696D50B2Q37385514-14FFDA3A-9FA2-4B24-B527-BF378E500562Q37793227-13CD6074-AFB4-4C81-BC28-0D45DC0D4FE7Q38057813-BED931C5-2B93-43F2-86AB-C3CD58387A25Q38079493-03E71A5D-3444-4F0C-A155-2D0B23B8CC7FQ38963328-F1D5BF9C-1FE6-4412-82D7-2BD1C478CAA2Q38967398-91255D65-DD14-4728-B4C2-2BC832C889B6Q39238942-547A1591-BC0F-4471-8B6C-F6DDD5F49D68Q39496658-F08D2732-70B6-4A37-9C25-695F46A88D27Q42872303-9179640F-077D-4F0D-AC10-FBBE1B0FFE50Q46566010-9AF4A000-053C-4ED2-A185-569171DF4E31Q47135864-D21B8535-EC2C-4271-82DC-2EEEEC6CE4C1Q55432588-17ADA022-EBD0-41BD-BBBB-FDE123D78234
P2860
Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Prevention of cachexia-like sy ...... tor type II-murine Fc protein.
@en
Prevention of cachexia-like sy ...... tor type II-murine Fc protein.
@nl
type
label
Prevention of cachexia-like sy ...... tor type II-murine Fc protein.
@en
Prevention of cachexia-like sy ...... tor type II-murine Fc protein.
@nl
prefLabel
Prevention of cachexia-like sy ...... tor type II-murine Fc protein.
@en
Prevention of cachexia-like sy ...... tor type II-murine Fc protein.
@nl
P2093
P356
P1476
Prevention of cachexia-like sy ...... tor type II-murine Fc protein.
@en
P2093
Jasbir S Seehra
Kate L Loveland
Kathryn Underwood
Martin M Matzuk
Qinglei Li
Ravi Kumar
P304
P356
10.1093/MOLEHR/GAM055
P577
2007-08-18T00:00:00Z